In a Canadian dispute for an antiviral product, CRA was retained to evaluate lost unit sales and lost profits suffered by a branded company from the allegedly improper sale of generic product in violation of a settlement agreement. At issue was the impact of the generic manufacturer flooding the market with product for a brief window of time before removing its product from the market and the effect on branded sales over time.
Were shareholders harmed by Senate Bill 21’s amendments to the Delaware General Corporation Law?
Delaware Governor Meyer signed into law Senate Bill 21 (SB21) in March 2025, updating Delaware’s corporate law, with some of the key provisions including safe...